Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase
Wan et al.,
Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase,
Journal of Infection, doi:10.1016/j.jinf.2023.02.029
Retrospective 30,040 hospitalized patients in Hong Kong, showing lower mortality with paxlovid treatment. Patients with contraindications to paxlovid were not excluded.
[Hoertel] find that over 50% of patients that died had a contraindication for the use of Paxlovid. Retrospective studies that do not exclude contraindicated patients may significantly overestimate efficacy.
risk of death, 28.0% lower, HR 0.72, p < 0.001, treatment 541 of 6,604 (8.2%), control 2,541 of 17,283 (14.7%), adjusted per study, multivariable, Cox proportional hazards.
|
risk of hospitalization, 24.0% lower, HR 0.76, p < 0.001, treatment 1,772 of 6,604 (26.8%), control 2,541 of 17,283 (14.7%), adjusted per study, multivariable, Cox proportional hazards.
|
risk of progression, 18.0% lower, HR 0.82, p < 0.001, treatment 1,816 of 6,604 (27.5%), control 2,541 of 17,283 (14.7%), adjusted per study, A&E admission, multivariable, Cox proportional hazards.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Wan et al., 22 Feb 2023, retrospective, China, peer-reviewed, 13 authors, study period 26 February, 2022 - 30 September, 2022.
Contact:
ewchan@hku.hk, wongick@hku.hk.
Abstract: Journal Pre-proof
Molnupiravir and nirmatrelvir-ritonavir reduce
mortality risk during post-acute COVID-19
phaseRunning title: Survival benefits of COVID-19
oral antiviral drugs
Eric Yuk Fai Wan
Boyuan Wang
Sukriti Mathur
Cheyenne I Ying Chan
Vincent Ka Chun Yan
Francisco Tsz Tsun Lai
Celine Sze Ling Chui
Xue Li
Carlos King Ho Wong
Philip Hei Li
Chak Sing Lau
Ian Chi Kei Wong
Esther Wai Yin Chan
PII:
S0163-4453(23)00117-2
DOI:
https://doi.org/10.1016/j.jinf.2023.02.029
Reference:
YJINF5894
To appear in: Journal of Infection
Accepted date: 18
Please cite this article as: Eric Yuk Fai Wan, Boyuan Wang, Sukriti Mathur,
Cheyenne I Ying Chan, Vincent Ka Chun Yan, Francisco Tsz Tsun Lai, Celine
Sze Ling Chui, Xue Li, Carlos King Ho Wong, Philip Hei Li, Chak Sing Lau,
Ian Chi Kei Wong and Esther Wai Yin Chan, Molnupiravir and nirmatrelvirritonavir reduce mortality risk during post-acute COVID-19 phaseRunning title:
Survival benefits of COVID-19 oral antiviral drugs, Journal of Infection, ()
doi:https://doi.org/10.1016/j.jinf.2023.02.029
This is a PDF file of an article that has undergone enhancements after acceptance,
such as the addition of a cover page and metadata, and formatting for readability,
but it is not yet the definitive version of record. This version will undergo
additional copyediting, typesetting and review before it is published in its final
form, but we are providing this version to give early visibility of the article.
Please note that, during the production process, errors may be discovered which
could affect the content, and all legal disclaimers that apply to the journal pertain.
© Published by Elsevier.
Title: Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute
COVID-19 phase
Authors: Eric Yuk Fai Wan, PhD1,2,3†; Boyuan Wang, MPH3†, Sukriti Mathur, BSc3†,
Cheyenne I Ying Chan, MPsyMed3, Vincent Ka Chun Yan, BPharm1; Francisco Tsz Tsun Lai,
PhD1,2; Celine Sze Ling Chui, PhD2,4,5; Xue Li, PhD1,2,6; Carlos King Ho Wong, PhD1,2,3; Philip
oo
f
Hei Li, MBBS6; Chak Sing Lau, MD6; Ian Chi Kei Wong, PhD1,2,7,8*, Esther Wai Yin Chan,
PhD1,2,7,9*
Centre for Safe Medication Practice and research, Department of Pharmacology and
e-
1
pr
Affiliations:
Pr
Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong
China
Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park,
3
ur
n
Hong Kong China
al
2
Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing
Faculty of Medicine, The University of Hong Kong, Hong Kong China
School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong
Jo
4
Kong China
5
School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong,
Hong Kong China
6
Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The
University of Hong Kong, Hong Kong China
7
Department of Pharmacy, The University of Hong Kong-Shenzhen Hospital, Shenzhen,
China
1
8
Aston Pharmacy School, Aston University, Birmingham, B4 7ET, UK
9
The University of Hong Kong Shenzhen Institute of Research and Innovation, Shenzhen,
China
† Co-first authors and contributed equally
oo
Running title: Survival benefits of COVID-19 oral antiviral drugs
f
* Co-Corresponding authors
pr
Correspondence
Dr Esther W. Chan, PhD
e-
Associate Professor, Department of Pharmacology and Pharmacy
Pr
Research Lead, Centre for Safe..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit